中国临床药理学杂志2018，Vol.34Issue(6)：622-625,4.DOI:10.13699/j.cnki.1001-6821.2018.06.004
尼莫地平联合阿卡波糖治疗糖尿病周围神经病变的临床研究
Clinical trial of nimodipine combined with acarbose in the treatment of patients with diabetic peripheral neuropathy
摘要
Abstract
Objective To observe the clinical efficacy of nimodipine and acarbose in the treatment of patients with diabetic peripheral neuropathy and its effect on nerve conduction velocity and nerve-related growth factor.Methods Seventy-six patients with diabetic peripheral neuropathy were randomly divided into treatment group and control group,38 cases in each group.Patients in control group were given nimodipine 40 mg,three times a day.On the basis of control group,treatment group was given acarbose 50 mg,three times a day.All patients were treated for a month.The clinical efficacy,nerve conduction velocity,nerve-related growth factor and adverse drug reactions in two groups were compared.Results After treatment,the total effective rates in treatment group and control group were 89.47％ (34 cases/38 cases) and 60.53％ (23 cases/38 cases),with significant difference(P ＜0.05).After treatment,the nerves peroneus communis,median nerve conduction velocity (MCV) and sensory nerve conduction velocity (SCV) in treatment group were (45.88 ±4.06),(51.69 ±4.56),(44.12 ±4.09) and (46.29 ± 5.71) m · s-1,had significant difference with those in control group,which were (41.16 ±3.83),(44.98 ±4.46),(39.52 ±3.19) and (43.13 ± 4.46) m· s-1 (all P ＜ 0.05).The levels of free fatty acid (FFA),tumor necrosis factor-α (TNF-α) and myelin basic protein (MBP) in treatment group were (471.45±44.28)μmol·L-1,(11.15 ± 1.18) pg · mL-1 and (1.90 ±0.14) μg · L-1,had significant difference with those in control group,which were (542.79 ±46.68) μmol ·L-1,(18.21 ±1.92) pg· mL-1 and (3.41 ±0.38) μg · L-1(all P＜0.05).The levels of vascular endothelial growth factor (VEGF) and brain-derived neurotrophic factor (BDNF) in treatment group were (943.39 ±97.85) and (4.87 ±0.58) ng· L-1,had significant difference with those in control group,which were (755.94 ±70.11) and (3.09 ±0.26) ng · L-1 (all P ＜0.05).The adverse drug reactions in treatment group were 1 case of diarrhea,3 cases of abdominal distension,with the incidence of 10.53％ (4 cases/38 cases).There were 1 case of mild dizziness,2 cases of digestive tract reaction,2 cases of bloating and mild abdominal discom fort in control group,with the incidence of 13.16％ (5 cases/38 cases).There was no significant difference in the incidence of adverse drug reactions between the two groups (P ＞ 0.05).Conclusion Nimodipine combined with acarbose in the treatment of diabetic peripheral neuropathy can effectively improve the nerve conduction velocity and nerve -related growth factor,and the clinical effect is good with high safety.关键词
尼莫地平/阿卡波糖/糖尿病周围神经病变/神经传导速度/神经相关生长因子Key words
nimodipine/acarbose/diabetic peripheral neuropathy/nerve conduction velocity/nerve-related growth factor分类
医药卫生引用本文复制引用
何兰香,计莉强,郑坚,张宴斌,葛敏..尼莫地平联合阿卡波糖治疗糖尿病周围神经病变的临床研究[J].中国临床药理学杂志,2018,34(6):622-625,4.基金项目
浙江省医学会临床科研基金资助项目(2013ZYC-A05) （2013ZYC-A05）
